The business case for Far-UVC is strongest for companies with highly-paid employees. They directly bear the productivity costs not only when an employee is sick, but also when they must stay home to care for a sick child. This makes caregiver absenteeism a significant, quantifiable ROI driver.

For new medical technologies to be adopted in over-burdened systems like the NHS, proof of efficacy in a lab is insufficient. The 'real acid test' is demonstrating that the technology works on the front lines of a busy, complex hospital. This real-world evidence is essential for gaining buy-in from skeptical staff.

The primary obstacle to widespread Far-UVC adoption isn't missing research, regulation, or high costs. It's a marketing and social normalization problem—shifting its perception from a niche gadget for early adopters to a standard public health utility like hand sanitizer or building ventilation.

The per-classroom cost of FAR-UVC technology (around $2,000 including installation) is low enough that a single motivated and affluent parent could fund a deployment. This provides a path to adoption that bypasses slow-moving institutional budgets and committees in schools.

The first undeniable proof of Far-UVC's effectiveness won't come from complex, society-wide studies. Instead, it will come from isolated, high-risk environments like tuberculosis wards or long-term care facilities, where a 90% reduction in transmission is a clear, dramatic signal that can drive adoption.

Rather than aiming directly for high-stakes clinical trials, Effion Health's go-to-market strategy begins with post-market, real-world evidence studies. This approach allows them to demonstrate their technology's value in a real-world setting, building a strong case for adoption in earlier, more critical drug development phases.

The primary reason FAR-UVC isn't widely deployed is a lack of public and institutional awareness. The technology is proven, commercially available, and increasingly affordable. The challenge is social diffusion and making it a normalized part of the built environment, like hand sanitizer or smoke alarms.

AI adoption in healthcare has accelerated by sidestepping slow enterprise sales cycles. Companies like Open Evidence offer free, consumer-like apps directly to doctors (prosumers). This bottom-up approach creates widespread use, forcing organizations to adopt the technology once a critical mass of their staff is already using it.

Strong data from controlled trials will open doors, but it won't guarantee broad adoption. True success comes from a product's predictable, reliable performance in everyday clinical settings, which are far more chaotic than an investigational site.